Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H13N5O5S2 |
Molecular Weight | 395.414 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O
InChI
InChIKey=RTXOFQZKPXMALH-GHXIOONMSA-N
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of estrogen administration on activities of testosterone 5alpha-reductase, alkaline phosphatase and arginase in the ventral and the dorsolateral prostates of rats. | 1975 Aug |
|
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure. | 2001 Feb |
|
A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study. | 2005 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. | 2005 Oct 1 |
|
A favorable response to steroid therapy in a child with drug-associated acute vanishing bile duct syndrome and skin disorder. | 2008 Apr |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
The total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Usual Adult Dose for Pneumonia: 300 mg orally every 12 hours for 10 to 14 days Acute exacerbations of chronic bronchitis: 300 mg orally every 12 hours for 5 to 10 days or 600 mg orally every 24 hours for 10 days Acute maxillary sinusitis: 300 mg orally every 12 hours or 600 mg orally every 24 hours for 10 days
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
WHO-ATC |
J01DD15
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
LIVERTOX |
161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
WHO-VATC |
QJ01DD15
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000175488
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25037
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | RxNorm | ||
|
CHEMBL927
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
91832-40-5
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
C056814
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
M3191
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | Merck Index | ||
|
91832-40-5
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
91832-40-5
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
6408
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
Cefdinir
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
6915944
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
C28914
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
SUB07386MIG
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY | |||
|
DB00535
Created by
admin on Mon Oct 21 19:50:40 UTC 2019 , Edited by admin on Mon Oct 21 19:50:40 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)